Bayer and Regeneron's hard-charging eye drug has traded its way to another victory. It won a recommendation from the U.K.'s cost-effectiveness watchdogs, on the strength of a pricing discount. Previously rejected as too expensive, Eylea is now in line for routine use by Britain's National Health Service.
Regeneron Pharmaceuticals is like a sports team on a streak that keeps bettors in the money by beating bookmaker odds time and again. This streak has gone uninterrupted for nearly two years.
Regeneron Pharmaceuticals has wagered on two preclinical programs for its growing business in ophthalmology drugs. The biotech heavyweight has forked over $20 million upfront and promised up to $45 million in milestones to its major partner Sanofi for full rights to the pair of antibody programs for use against eye diseases.
Allergan has slammed the brakes on two planned late-stage studies of a pair of key therapeutics in its pipeline, saying that investigators have to go back to the mid-stage drawing board in order to see whether their drugs work as hoped or whether a new formulation can salvage their efforts.
How much is a wildly successful drug worth? For Regeneron's top executives, the answer is $140 million. With its vision-loss drug beating all sales expectations for its first year on the market, the company's 5 highest-paid managers won $140,695,118 in 2012 compensation.
Just what does Sanofi ($SNY) have planned with Regeneron ($REGN)? The two companies raised eyebrows this morning with the announcement that Sanofi would be snapping up enough Regeneron stock to surpass the $500 million antitrust-notification threshold.
Novartis is one step closer to marketing Lucentis in a new group of patients. The National Institute for Health and Clinical Excellence officially changed its mind on the Swiss drugmaker's eye treatment, recommending the pricey injection for use in diabetics.
Bayer and partner Regeneron have notched another win for Eylea, getting approval for the eye drug in Europe for treating wet age-related macular degeneration.
Regeneron ($REGN) is eyeing a big expansion at an upstate New York plant now that its macular degeneration drug has taken off. The company plans to spend $70 million on new buildings and upgrades--and add 300 jobs--at the Albany-area facility.
Bayer Healthcare is on a roll, and it has no intention of easing off the gas now. Emboldened by rising sales of Xarelto, pumped by the prospects of the macular degeneration drug Eylea and optimistic about the newly approved cancer drug Stivarga, Bayer's pharma division has outlined some ambitious plans for its $4 billion annual R&D budget.